| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/29/2001 | EP1127076A2 Crystallized form of fc epsilon receptor alpha chain, its 3-d model and uses thereof |
| 08/29/2001 | EP1127075A2 A method of treating tumors using fas-induced apoptosis |
| 08/29/2001 | EP1127072A1 Method for detecting and purifying tcd8+ lymphocyte populations, specific of peptides present in the context of hla |
| 08/29/2001 | EP1127071A1 Compounds with growth hormone releasing properties |
| 08/29/2001 | EP1127070A2 $i(IKAROS) ISOFORMS AND MUTANTS |
| 08/29/2001 | EP1127069A2 Biological materials and methods useful in the diagnosis and treatment of prion diseases |
| 08/29/2001 | EP1127068A1 Immunotherapeutic methods using epitopes of wt-1 and gata-1 |
| 08/29/2001 | EP1127067A2 Inhibition of transglutaminase-mediated microbial interaction with a mammalian host |
| 08/29/2001 | EP1126880A2 Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
| 08/29/2001 | EP1126879A1 Gene therapy for regulating smooth muscle cell tone |
| 08/29/2001 | EP1126878A1 Heparanase activity neutralizing anti-heparanase monoclonal antibody |
| 08/29/2001 | EP1126874A2 Multicomponent meningococcal vaccine |
| 08/29/2001 | EP1126873A1 Method for enhancing proliferation of inner ear hair cells using ligands for her2 and/or her3 receptors |
| 08/29/2001 | EP1126871A2 Combination therapy with vip antagonist |
| 08/29/2001 | EP1126870A2 Use of vegf-c or vegf-d gene or protein to prevent restenosis |
| 08/29/2001 | EP1126869A2 Methods for regulating angiogenesis and vascular integrity using trk receptor ligands |
| 08/29/2001 | EP1126868A2 Method of modulating hair growth |
| 08/29/2001 | EP1126867A2 A composition for the prevention and/or treatment of atherosclerosis |
| 08/29/2001 | EP1126866A2 A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure |
| 08/29/2001 | EP1126865A2 Methods and compositions for treating or preventing peripheral neuropathies |
| 08/29/2001 | EP1126863A1 Vascular endothelial growth factor-like protein from orf virus nz2 binds and activates mammalian vegf receptor-2 |
| 08/29/2001 | EP1126849A1 Heterocyclic potassium channel inhibitors |
| 08/29/2001 | EP1126847A1 Method for improving the pharmacokinetics of tipranavir |
| 08/29/2001 | EP1126845A2 New use of immunosuppressants for mmp-mediated diseases |
| 08/29/2001 | EP1126842A2 Inhibition of the formation of vascular hyperpermeability |
| 08/29/2001 | EP1126836A1 Benzamide potassium channel inhibitors |
| 08/29/2001 | EP1126812A1 Treatment of skin with adenosine or adenosine analog |
| 08/29/2001 | EP1126762A1 Energetic rehydration fluid composition in particular for young animals no longer able to digest milk normally |
| 08/29/2001 | EP1000089A4 Collagen type i and type iii adhesive compositions |
| 08/29/2001 | EP0914043A4 Implantable agarose-collagen beads containing cells which produce a diffusible biological product, and uses thereof |
| 08/29/2001 | EP0831782A4 Methods and system for processing dispersible fine powders |
| 08/29/2001 | EP0828758B1 Chimeric fatty body-pro-grf analogs with increased biological potency |
| 08/29/2001 | EP0792290B1 Acylated insulin |
| 08/29/2001 | EP0751709B1 Use of bcl-2 for the manufacture of medicaments for the therapeutic treatment and prevention of diseases |
| 08/29/2001 | EP0730473B1 Hirudin conjugates from hirudin and lipophilic compounds |
| 08/29/2001 | EP0687181B1 Use of thymosin for treating hepatitis c in non-responders to interferon treatment |
| 08/29/2001 | EP0618925B1 Antisense oligonucleotides |
| 08/29/2001 | CN1310759A Therapeutic and diagnostic domain 1 & beta 2GP1 polypeptides and methods of using same |
| 08/29/2001 | CN1310724A Novel peptides for use in immunotherapy of autoimmune diseases |
| 08/29/2001 | CN1310723A HLA-A2 restraint tumor antigen peptide originating in SART-1 |
| 08/29/2001 | CN1310630A Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides |
| 08/29/2001 | CN1310627A Hair growth/maintenance compositions and methods involving the same |
| 08/29/2001 | CN1310626A Hybrid polypeptides with enhanced pharmacokinetic properties |
| 08/29/2001 | CN1310625A Use of alpha1 & beta1 integrin receptor inhibitors and TGF-beta1 inhibitors in the treatment of kidney disease |
| 08/29/2001 | CN1310623A Bioimplant formulation |
| 08/29/2001 | CN1310618A Inhibition of binding of Hox and homeodomain containing proteins and uses thereof |
| 08/29/2001 | CN1310179A Oxamide being as IMPDH inhibitor |
| 08/29/2001 | CN1310024A Microencapsulated compound nutrient complementing agent |
| 08/29/2001 | CN1310023A Specific immunological inhibitor |
| 08/29/2001 | CN1310022A Method of making medicine from extracting metabolic product of staphylococcus aureus and thallus protein |
| 08/29/2001 | CN1309970A Application of uridine phosphorylase inhibitor and composition containing the same |
| 08/29/2001 | CN1070198C Isolated nucleic acid molecule of coded tumor rejection antigen precursor DAGE and its application |
| 08/29/2001 | CA2337661A1 Stabilized granulocyte colony stimulating factor |
| 08/29/2001 | CA2335436A1 Novel core 2 beta-1,6-n-acetylglycosaminyl transferase gene |
| 08/28/2001 | US6281376 Therapeutic compound—fatty acid conjugates |
| 08/28/2001 | US6281352 Antiinflammatory agents |
| 08/28/2001 | US6281335 Hybridoma and anti-KC-4 humanized monoclonal antibody |
| 08/28/2001 | US6281332 Hedgehog-derived polypeptides |
| 08/28/2001 | US6281330 Multimeric forms of members of the steroid/thyroid superfamily of receptors with the ultraspiracle receptor |
| 08/28/2001 | US6281252 Administering a aliphatic amine polymer; therapy for kidney stones |
| 08/28/2001 | US6281247 Salt forms of (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoyl)-2-(2-naphthyl)ethyl)amide |
| 08/28/2001 | US6281200 Functional characterization of the C-C chemokine-like molecules encoded by molluscum contagiosum virus types 1 and 2 |
| 08/28/2001 | US6281195 Matrix-free osteogenic devices, implants and methods of use thereof |
| 08/28/2001 | US6281194 E.g., (s)-(1-((4-benzyloxy-benzyl)-(((1-phenyl-cyclobutylmethyl)-car bamoyl)-methyl)-carbamoyl)-2-(1h-imidazol-4-yl)-ethyl)-carbami c acid benzyl ester |
| 08/28/2001 | US6281193 In autoimmune diseases in general, or graft-versus-host reactions in particular. |
| 08/28/2001 | US6281192 Derived from mammalian milk or milk byproducts. |
| 08/28/2001 | US6281191 Compositions and methods for treating hepatitis-C |
| 08/28/2001 | US6281190 Human LEA-motif developmental protein |
| 08/28/2001 | US6281175 Medical emulsion for lubrication and delivery of drugs |
| 08/28/2001 | US6281015 Introducing a microsphere with a bioactive factor to a hepatocyte seeded biodegradable polymer matrix into a transplantation site; enhancing survival and proliferation of transplanted cells |
| 08/28/2001 | US6281013 In vitro fertilization; treating female with hypothalamic or pituitary hormone, retrieving oocyte, exposure to meiosis activating substance |
| 08/28/2001 | US6281000 Dna fragment cloning into genome of recombinant adenoviral plasmid vector; human gene therapy |
| 08/28/2001 | US6280994 Zace 1: a human metalloenzyme |
| 08/28/2001 | US6280991 Engineered cytotoxic ribonclease |
| 08/28/2001 | US6280987 Anti-cocaine catalytic antibody |
| 08/28/2001 | US6280978 Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| 08/28/2001 | US6280975 Adjusted interleukin polypeptide for use in the treatment of myelomas, tumors, osteoporosis and autoimmune diseases |
| 08/28/2001 | US6280974 Nucleotide sequence coding viral protein; for use as diagnostic tool in detection of viral diseases |
| 08/28/2001 | US6280971 Polynucleotide associated with detection of staphylococcus; for use in screening bactericides |
| 08/28/2001 | US6280969 Growth arrest homeobox gene |
| 08/28/2001 | US6280968 Human PEC-60-like protein and DNA encoding the same |
| 08/28/2001 | US6280964 Binding sites for phosphotyrosine binding domains |
| 08/28/2001 | US6280963 Essential fungal genes and their use |
| 08/28/2001 | US6280958 Detecting preferential antibodies in sample; incubate sample with antigenic protein and detect immune complex |
| 08/28/2001 | US6280957 Preventing graft rejection in humans; administer human a modulator of ligand activity, insert hematopoietic stem cells and graft into human, monitor response to grafts |
| 08/28/2001 | US6280956 Antibodies to bladder cancer nuclear matrix proteins and their use |
| 08/28/2001 | US6280944 Assay for pathogenicity of anti-DNA antibodies |
| 08/28/2001 | US6280936 Method for screening nucleic acid catalysts |
| 08/28/2001 | US6280774 Extraction of bile from animals, stimulating monocytes and macrophages and modulating tumor necrosis factor production |
| 08/28/2001 | US6280770 Microemulsions as solid dosage forms for oral administration |
| 08/28/2001 | US6280747 Cosmetic or dermatological composition contacting at least one natural or recombinant spider silk or an analog |
| 08/28/2001 | US6280739 Method of inhibiting angiogenesis using secreted proteins |
| 08/28/2001 | US6280736 Stable extract of Hypericum perforatum L.,process for preparing the same and pharmaceutical compositions |
| 08/28/2001 | US6280735 Polypeptides of riboflavin specific deaminase family |
| 08/28/2001 | US6280733 Purified polypeptide comprising specified amino acid sequence, wherein said polypeptide binds to microtubules |
| 08/28/2001 | US6280732 Administering intracerebrally al-1 immunoadhesin comprising mature al-1 polypeptide having specified amino acid sequence in amount effective to activate autophosphorylation of rek7 |
| 08/28/2001 | US6280731 Monoclonal antibody which binds to human von willebrand factor, inhibits ristocetin-dependent and botrocetin-dependent binding of human von willebrand factor to human platelets, exhibits antithrombotic action in guinea pigs |
| 08/28/2001 | US6280730 Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin |
| 08/28/2001 | US6280729 Treating christmas disease in patient by administering effective amount of therapeutic composition comprising storage stable aqueous solution of purified factor ix |
| 08/28/2001 | US6280728 Treatment of hepatitis C virus infection using a protease and a flavonoid |